Multipl MİYELOM Seyrinde Lenalidomid İdamesi Altında Gelişen Sekonder B-Hücreli Akut Lenfoblastik Lösemi
Özet
Multipl miyelomda (MM) modern tedavi yaklaşımları sayesinde sağkalım süreleri belirgin olarak uzamıştır. Ancak sağkalımdaki bu artışa paralel olarak, uzun dönem tedaviye bağlı komplikasyonlar daha sık bildirilmeye başlanmıştır. Bu yazıda, iki kez OHKHN uygulanmış ve uzun süreli lenalidomid idame tedavisi alan MM hastasında gelişen sekonder Philadelphia kromozomu (Ph) pozitif B-hücreli akut lenfoblastik lösemi (B-ALL) olgusu sunulmuştur. Bu olgu, MM hastalarında gelişen yeni sitopenilerin yalnızca relaps veya tedavi toksisitesi açısından değil, tedavi ilişkili sekonder hematolojik maligniteler açısından da dikkatle değerlendirilmesi gerektiğini göstermektedir.
Referanslar
Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies in multiple myeloma. Lancet Oncol. 2014;15(3):333-342.
Holstein SA, Suman VJ, McCarthy PL. Second malignancies in multiple myeloma: an overview and IMWG consensus. Blood Cancer J. 2017;7:e573.
Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676-681.
Thomas A, Mailankody S, Korde N, et al. Secondary acute lymphoblastic leukemia in patients with multiple myeloma. Leuk Lymphoma. 2015;56(8):2360-2364.
Rosenberg AS, Brunson A, Paulus JK, et al. Therapy-related acute lymphoblastic leukemia. Blood Rev. 2022; 54:100930.
Mouhieddine TH, Sperling AS, Redd R, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996.
Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022;40(2):189-201.
Bolton KL, Ptashkin RN, Gao T, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2023;142(18):1591-1605.
Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related hematologic malignancies. Nature. 2015;518(7540):552-555.
McCarthy PL, Holstein SA, Petrucci MT, et al. Long-term follow-up of IFM 2005-02 lenalidomide maintenance trial. J Clin Oncol. 2023;41(16):2900-2908.
Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for myeloma. N Engl J Med. 2012;366(19):1782-1791.
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289.
Ko H, Lee DH, Kim SJ, et al. Risk of secondary malignancies after multiple myeloma: a nationwide case-control cohort study. Clin Lymphoma Myeloma Leuk. 2024;24(2):e95-e103.
Mirgh S, et al. Secondary primary malignancies in multiple myeloma patients undergoing autologous transplantation: long-term single-center experience. Indian J Hematol Blood Transfus. 2026. [Epub ahead of print].
Rosenberg AS, Brunson A, Tuscano J, et al. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J. 2021;11(1):5.
Fei F, Reddy V, Rosenblum F. Secondary primary malignancies in patients with multiple myeloma: a single institution experience. Hematol Oncol. 2021;39(5):674-679.
